Saturday 17 October 2026
Export VVOS’s income statement to Excel — free account
Vivos Therapeutics, Inc.
VVOS Healthcare Medical Devices
Vivos Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $17.4 million, up 16.0% from fiscal 2024. In the quarter to June 2026, revenue grew 34.9%, EPS grew 43.6%, free cash flow grew 16.4% and total debt rose 2.79%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.13
0.01
−7.14%
Follow VVOS
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
2 | 5 | 3 | 2 | 4 | 4 | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z-Score |
(9.08) | (9.01) | (15.83) | (12.46) | 0.42 | 3.02 | — | — | — |
P/S ratio |
1.20 | 1.43 | 1.04 | 1.06 | 2.83 | 5.82 | 8.76 | 8.76 | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
(25.19) | (24.92) | (42.01) | (31.24) | (2.30) | (2.38) | (25.93) | (16.73) | — |
Beneish M-Score |
(1.44) | (0.97) | (3.63) | (4.10) | (2.88) | (3.25) | (5.47) | — | — |
P/Operating CF |
(5.47) | (7.32) | (5.23) | (5.68) | (11.59) | (21.02) | (166.50) | (166.50) | — |
P/B ratio |
0.00 | 2.71 | 35.00 | 3.55 | 1.87 | 4.50 | 0.00 | 0.00 | — |
Price to Tangible BV |
0.00 | 4.58 | 0.00 | 10.29 | 2.14 | 5.44 | 0.00 | 0.00 | — |
EV/Sales |
1.59 | 1.16 | 1.08 | 0.99 | 1.49 | 4.53 | 8.75 | 8.75 | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
(1.81) | (1.37) | (1.24) | (0.81) | (1.60) | (10.41) | (15.15) | (15.15) | — |
EV/FCF |
(1.57) | (1.31) | (1.16) | (0.78) | (1.39) | (10.20) | (14.75) | (14.75) | — |
Quick Ratio |
0.20 | 1.34 | 0.25 | 0.58 | 3.43 | 2.52 | 0.16 | 0.86 | — |
Current Ratio |
0.24 | 1.50 | 0.34 | 0.80 | 3.64 | 2.60 | 0.22 | 0.87 | — |
Net Debt/EBITDA |
(0.37) | 0.59 | 0.10 | 0.05 | 1.16 | 1.49 | (0.33) | 0.07 | — |
Debt/Assets |
35.07% | 0.00% | 0.00% | 17.59% | 3.75% | 5.09% | 49.12% | 8.37% | 0.00% |
Debt/Equity |
(5.69) | 0.00 | 0.00 | 0.50 | 0.05 | 0.08 | (1.26) | 0.13 | — |
Asset Turnover |
0.86 | 1.16 | 1.13 | 0.68 | 0.57 | 0.79 | 1.45 | 0.92 | — |
Operating CF/Net income |
0.72 | 1.14 | 0.88 | 0.82 | 0.78 | 0.32 | 0.45 | 0.57 | — |
Capex/Depreciation |
(1.79) | (0.98) | (1.29) | (1.38) | (3.27) | (0.17) | (0.23) | 0.00 | — |
Interest Coverage |
— | — | — | (281.25) | (1,455.86) | (125.42) | (76.70) | (161.87) | — |
| (648.99%) | (266.25%) | (521.22%) | (157.19%) | (95.57%) | (257.45%) | (1,248.00%) | (1,002.20%) | — | |
| (104.71%) | (85.62%) | (111.11%) | (100.59%) | (68.75%) | (109.42%) | (149.21%) | (230.11%) | — | |
ROIC |
(237.15%) | (412.15%) | 0.00% | (423.39%) | (459.22%) | (752,500.00%) | (2,225.84%) | 0.00% | — |
Return on Tangible Assets |
213.09% | (191.80%) | 897.16% | (1,408.45%) | (89.61%) | (133.99%) | 196.89% | (941.85%) | — |
Average Days of Receivables |
33.08 | 10.44 | 5.34 | 10.41 | 37.16 | 42.32 | 30.63 | 57.29 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
166.98% | 130.46% | 180.76% | 214.56% | 185.62% | 140.85% | 162.23% | 275.19% | — |
Intangible Assets out of Total Assets |
0.50 | 0.21 | 0.30 | 0.23 | 0.09 | 0.12 | 0.45 | 0.60 | 0.00 |
Share Based Compensation of Revenue |
3.79% | 5.35% | 13.98% | 19.39% | 17.23% | 46.81% | 18.11% | 0.00% | — |
Graham Net Nets |
(1.07) | 0.01 | (0.55) | (0.21) | 0.40 | 0.16 | 0.03 | 0.03 | — |
Graham Number |
2.65 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
(101.97%) | (67.83%) | (93.64%) | (141.89%) | (43.56%) | (15.99%) | (5.25%) | (5.25%) | — |
Free Cash Flow Yield |
(84.41%) | (61.57%) | (88.63%) | (120.38%) | (37.95%) | (7.63%) | (6.77%) | (6.77%) | — |
Revenue per Share |
1.70 | 2.99 | 11.32 | 17.40 | 19.88 | 25.38 | 23.10 | 5.21 | — |
Operating CF per Share |
(1.49) | (2.53) | (9.80) | (21.27) | (18.53) | (11.03) | (10.83) | (7.45) | — |
Capex per Share |
(0.23) | (0.11) | (0.66) | (1.00) | (2.82) | (0.23) | (0.36) | 0.00 | — |
Free Cash Flow per Share |
(1.71) | (2.64) | (10.46) | (22.27) | (21.35) | (11.27) | (11.18) | (7.45) | — |
Cash per Share |
0.20 | 1.25 | 1.35 | 3.82 | 28.29 | 35.37 | 0.95 | 1.72 | — |
Shareholders Equity per Share |
(0.15) | 1.58 | 0.34 | 5.21 | 30.07 | 32.86 | (5.97) | 7.55 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
(0.15) | 1.58 | 0.34 | 5.21 | 30.07 | 32.86 | (5.97) | 7.55 | — |
Free Cash Flow |
(17.60) | (13.26) | (12.75) | (20.51) | (18.13) | (5.80) | (5.52) | (5.42) | — |
Working Capital |
(13.69) | 2.50 | (4.83) | (1.39) | 19.82 | 12.55 | (7.11) | (0.28) | — |
Capital Expenditures |
(2.34) | (0.57) | (0.80) | (0.92) | (2.40) | (0.12) | (0.18) | (1.25) | — |
Net Current Asset Value |
(22.32) | 0.14 | (7.86) | (3.49) | 19.17 | 11.98 | (8.51) | (0.83) | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
0.13 | 0.04 | 0.06 | 0.06 | 0.14 | 0.01 | 0.02 | 0.00 | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.35 | 0.18 | 0.19 | 0.22 | 0.26 | 0.82 | 0.66 | 0.48 | — |
Cash ROIC |
(189.27%) | (93.28%) | (620.69%) | (191.10%) | (35.67%) | (15.93%) | (446.36%) | (72.87%) | — |
Accounts Receivable Turnover |
17.35 | 47.57 | 41.88 | 14.73 | 10.44 | 10.58 | 14.69 | 4.89 | — |
Accounts Payable Turnover |
4.97 | 3.71 | 3.11 | 5.15 | 5.03 | 2.85 | 3.51 | 2.17 | — |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
88.80 | 66.66 | 141.58 | 85.76 | 78.44 | 107.45 | 144.53 | 102.26 | — |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Receivables |
1.01 | 0.32 | 0.33 | 1.09 | 1.62 | 1.24 | 0.78 | 0.78 | — |
Average Payables |
1.39 | 1.62 | 1.78 | 1.17 | 0.85 | 0.93 | 0.78 | 0.78 | — |
Average Assets |
20.22 | 13.01 | 12.23 | 23.70 | 29.51 | 16.44 | 7.88 | 4.10 | — |
Average Common Equity |
3.26 | 4.18 | 2.61 | 15.17 | 21.23 | 6.99 | 0.94 | 0.94 | — |
Columns are period end dates